Evidence map›Paper›PMID 36862005›Full record

ArticleMolecular oncology2023

MicroRNA 483-3p overexpression unleashes invasive growth of metastatic colorectal cancer via NDRG1 downregulation and ensuing activation of the ERBB3/AKT axis.

Ermes Candiello, Gigliola Reato, Federica Verginelli, Gennaro Gambardella, Antonio D Ambrosio, Noemi Calandra, Francesca Orzan, Antonella Iuliano, Raffaella Albano, Francesco Sassi and 5 more

Open access · goldAbstract read
In one paragraph

Article in Molecular oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.9field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 6 citations in OpenAlex.

  1. Review
  2. Article
  3. Insight into the Regulation of NDRG1 Expression.International journal of molecular sciences · 2025
    Review
  4. Impact of Mir196a-2 Genotypes on Colorectal Cancer Risk in Taiwan.International journal of molecular sciences · 2023
    Article
  5. The Role of Tumor Stem Cells in Colorectal Cancer Drug Resistance.Cancer control : journal of the Moffitt Cancer Center
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 5 institutions in 2 countries.

Ermes CandielloLaboratory of Cancer Stem Cell Research, Candiolo Cancer Institute, FPO-IRCCS, Turin, Italy.
Gigliola ReatoLaboratory of Cancer Stem Cell Research, Candiolo Cancer Institute, FPO-IRCCS, Turin, Italy.ORCID 0000-0003-3463-2930
Federica VerginelliLaboratory of Cancer Stem Cell Research, Candiolo Cancer Institute, FPO-IRCCS, Turin, Italy.
Gennaro GambardellaTelethon Institute of Genetics and Medicine (TIGEM), Naples, Italy.ORCID 0000-0001-7517-1347
Antonio D AmbrosioLaboratory of Cancer Stem Cell Research, Candiolo Cancer Institute, FPO-IRCCS, Turin, Italy.
Noemi CalandraLaboratory of Cancer Stem Cell Research, Candiolo Cancer Institute, FPO-IRCCS, Turin, Italy.
Francesca OrzanLaboratory of Cancer Stem Cell Research, Candiolo Cancer Institute, FPO-IRCCS, Turin, Italy.
Antonella IulianoTelethon Institute of Genetics and Medicine (TIGEM), Naples, Italy.
Raffaella AlbanoLaboratory of Cancer Stem Cell Research, Candiolo Cancer Institute, FPO-IRCCS, Turin, Italy.
Francesco SassiTranslational Cancer Medicine, Candiolo Cancer Institute, FPO-IRCCS, Turin, Italy.
Paolo LuraghiLaboratory of Cancer Stem Cell Research, Candiolo Cancer Institute, FPO-IRCCS, Turin, Italy.
Paolo M ComoglioIFOM, FIRC Institute of Molecular Oncology, Milan, Italy.
Andrea BertottiDepartment of Oncology, University of Turin Medical School, Italy.
Livio TrusolinoDepartment of Oncology, University of Turin Medical School, Italy.
Carla BoccaccioLaboratory of Cancer Stem Cell Research, Candiolo Cancer Institute, FPO-IRCCS, Turin, Italy.ORCID 0000-0003-2620-9083
Candiolo Cancer Institute · ITDepartment of Medical Sciences · BYFederico II University Hospital · ITIFOM · ITTelethon Institute Of Genetics And Medicine · IT

Funding

Cancer Research UK A26825Cancer Research UK A28223
6 · The paper itself

Abstract

In colorectal cancer, the mechanisms underlying tumor aggressiveness require further elucidation. Taking advantage of a large panel of human metastatic colorectal cancer xenografts and matched stem-like cell cultures (m-colospheres), here we show that the overexpression of microRNA 483-3p (miRNA-483-3p; also known as MIR-483-3p), encoded by a frequently amplified gene locus, confers an aggressive phenotype. In m-colospheres, endogenous or ectopic miRNA-483-3p overexpression increased proliferative response, invasiveness, stem cell frequency, and resistance to differentiation. Transcriptomic analyses and functional validation found that miRNA-483-3p directly targets NDRG1, known as a metastasis suppressor involved in EGFR family downregulation. Mechanistically, miRNA-483-3p overexpression induced the signaling pathway triggered by ERBB3, including AKT and GSK3β, and led to the activation of transcription factors regulating epithelial-mesenchymal transition (EMT). Consistently, treatment with selective anti-ERBB3 antibodies counteracted the invasive growth of miRNA-483-3p-overexpressing m-colospheres. In human colorectal tumors, miRNA-483-3p expression inversely correlated with NDRG1 and directly correlated with EMT transcription factor expression and poor prognosis. These results unveil a previously unrecognized link between miRNA-483-3p, NDRG1, and ERBB3-AKT signaling that can directly support colorectal cancer invasion and is amenable to therapeutic targeting.

Indexed as

Colonic NeoplasmsColorectal NeoplasmsMicroRNAsRectal NeoplasmsCell Line, TumorCell MovementDown-RegulationEpithelial-Mesenchymal TransitionGene Expression Regulation, NeoplasticHumansNeoplasm InvasivenessProto-Oncogene Proteins c-aktTranscription FactorsMicroRNAsMIRN483 microRNA, humanProto-Oncogene Proteins c-aktTranscription Factorscancer stem cellcolorectal cancerERBB3metastasismiRNA-483-3pNDRG1

Identifiers

PMID36862005
PMCPMC10323897
OpenAlexW4322757413

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.